SAMe, Methyl Folate, and Omega-3 Depression Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropsychiatric conditions like Major Depressive Disorder are limited by toxicity, side effects, and resistance, particularly in pediatric populations, with prescription antidepressants posing risks of suicidal ideation and adverse interactions.
Innovation Solution
A pharmaceutical composition combining S-adenosyl methionine (SAMe), methyl folate, and omega-3 fatty acids, optionally with vitamin B12, to provide anti-depressant and mood-stabilizing effects with reduced side effects, suitable for various conditions including depression, anxiety, and other neuropsychiatric disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prescription antidepressants are used to treat depression, then anti-depressant effect is achieved, but toxicity and side effects increase
Solution Approach 1:
The patent combines multiple natural compounds (SAMe, omega-3 fatty acids, and other nutrients) into a composite therapeutic formulation. This composite approach leverages synergistic effects among components to achieve antidepressant efficacy while minimizing individual component toxicity, directly addressing the contradiction between effectiveness and safety
Solution Approach 2:
The invention uses naturally occurring, readily available compounds that can be obtained through diet or supplementation rather than complex synthetic pharmaceuticals. These natural compounds are metabolized and eliminated more safely by the body, reducing accumulation and long-term toxicity concerns
2Reliability
If prescription antidepressants are used to treat depression, then mood improvement is achieved, but suicidal ideation risk increases
Solution Approach 1:
The therapeutic composition supports the body's natural mood-regulating mechanisms by providing precursors for neurotransmitter synthesis (SAMe for serotonin and dopamine production, omega-3s for brain cell membrane health). This self-service approach enhances endogenous protective mechanisms rather than imposing external chemical forces that may trigger suicidal ideation
3Reliability
If prescription antidepressants are used to treat depression, then treatment efficacy is achieved, but medication interactions increase
Solution Approach 1:
The natural compounds in the composition act as intermediaries that support overall neurological health and neurotransmitter function without directly interfering with the metabolic pathways of prescription medications. SAMe and omega-3s work through multiple downstream mechanisms rather than competing for the same enzymatic targets, reducing interaction potential while maintaining treatment efficacy
4Object-affected harmful factors
If natural alternative therapies are used to treat depression, then side effects are reduced, but treatment efficacy decreases
Solution Approach 1:
The patent merges multiple beneficial natural compounds into a single synergistic formulation. SAMe provides methyl groups for neurotransmitter synthesis, omega-3 fatty acids support brain cell membrane integrity and reduce inflammation, and additional nutrients address cofactor requirements. This combination creates a unified therapeutic effect greater than the sum of individual components, achieving efficacy comparable to prescription medications without their side effects
Data Source
AI summary
Disclosed are a novel combination of specific therapeutics selected from S-adenosyl methionine or a salt thereof, folic acid or a metabolite or salt thereof, and one or more omega-3 fatty acids or salts thereof, useful for a variety of conditions, as discussed herein. Methods of treatment include the treatment of neuropsychiatric conditions, such as depression.